🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Filana Therapeutics, Inc. FLNA PHARMA

Healthcare · Biotechnology · United States
https://www.filanatx.com
Company Profile ↓
$0.80
-65.04% 1Y
Mkt Cap$38.65M
P/E-0.92
P/B0.61
52W High$4.64
52W Low$0.80
Book Value$1.32
EPS (TTM)$-0.87

Company Overview

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 18.9% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue +277.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 18.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:18.92%
1 Year:277.58%

Stock Price Performance

1 Year:-65.04%
6 Months:-62.40%
3 Months:-44.25%
1 Month:-20.28%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$0.80 $4.64
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)31.25 · Neutral
Price Performance
1M-20.28%
3M-44.25%
6M-62.40%
1Y-65.04%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 18.9% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 82.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.92
Industry PE
24.83
Forward P/E
-
PEG Ratio
1.62
Book Value
$1.32
Price to Book
0.61
P/S
1.17
EV/EBITDA
3.48
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
18.92%
Profit 5Y
-
Revenue (YoY)
277.58%
Earnings (YoY)
-

Profitability & Returns

ROCE
-128.00%
ROE
-55.78%
ROA
-7.14%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.22
EPS (TTM)
$-0.87

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
2.06
Current Ratio
2.08
Debt
$0
Total Assets
$108.37M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
2.05%
Chg in Prom Hold
-
FII / Inst Holding
26.72%
Chg in FII Hold
-1.89%

Financial Snapshot

Enterprise Value
$38.65M
Total Revenue (TTM)
$41.12M
EBITDA
$-12.69M
Free Cash Flow
$3.98M
Operating Cash Flow
$-28.70M
Shares Outstanding
48.31M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 FLNA Filana Therapeutics, Inc. PHARMA 0.80 -0.92 $38.65M 0.00% -128.00% -55.78% 18.92% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2014Jun 2014Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Operating Income -3.46M-3.26M-3.54M--2.60M-3.39M-3.69M--5.83M-3.04M-3.54M--2.76M-4.17M-2.60M-2.17M-2.46M-1.28M-1.45M-1.15M-779.00K-1.22M-1.16M-1.44M-3.53M-5.14M-9.75M-17.82M-19.92M-21.34M-26.51M-28.78M-27.88M-19.93M-61.40M-30.62M-24.59M-45.39M-11.86M-11.17M
Net Income -3.45M-3.25M-3.53M-2.16M-2.58M-3.37M-3.67M-4.52M-5.79M-3.02M-3.52M-2.52M-2.74M-4.16M-2.59M-2.16M-2.45M-1.27M-1.36M-1.06M-697.00K-1.15M-1.14M-1.43M-3.53M-5.12M-9.56M-17.53M-19.33M-20.26M-24.27M-26.38M-25.65M25.04M6.16M-27.94M-23.40M-44.22M-10.81M-10.33M
Diluted EPS ----------------------------0.44-0.48--0.58-0.63-0.61-0.430.13-0.58-0.48-0.92-0.22-
R&D Expense 2.15M1.94M2.12M-1.14M1.99M2.36M-3.60M1.59M2.66M-1.39M3.06M1.62M1.07M1.46M1.46M574.00K308.00K---------18.53M22.12M24.97M23.60M16.23M15.20M17.68M13.67M5.12M3.96M4.54M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 20.56M16.81M11.48M10.89M41.12M------------
Operating Income -6.75M-13.70M-3.51M-3.90M31.36M-12.43M-14.20M-14.96M-11.95M-6.66M-4.96M-6.45M-32.87M-80.02M-105.96M-141.45M-95.39M
Net Income -3.47M-12.02M-2.61M-3.45M31.54M-12.39M-14.14M-14.85M-11.91M-6.56M-4.63M-6.33M-32.38M-76.25M-97.22M-24.34M-90.97M
Diluted EPS ---0.06-0.080.70-0.27-0.31-------1.90-2.32-1.46-1.88
R&D Expense 21.06M15.75M8.30M7.61M4.92M7.31M9.10M9.18M7.62M2.97M--24.81M68.03M89.42M69.64M26.59M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --99.19M98.96M56.86M50.10M40.91M31.92M19.30M10.83M20.14M23.49M94.30M266.78M234.83M151.66M157.53M118.36M
Total Equity 104.29M108.25M32.93M44.39M13.14M48.30M40.06M29.37M18.64M9.70M19.63M22.10M92.20M253.91M227.54M137.47M145.70M74.40M
Cash & Equivalents 153.16M35.79M4.80M73.14M49.35M48.59M40.59M31.30M16.61M10.48M19.81M23.08M93.51M233.44M201.01M121.14M128.57M95.50M
Total Liabilities --66.26M54.57M43.72M1.80M850.00K2.55M665.00K1.13M511.00K1.39M2.10M12.87M7.29M14.20M11.83M43.95M
Current Liabilities --14.07M13.27M10.00M1.80M850.00K2.55M665.00K1.13M511.00K1.39M1.86M12.53M7.06M14.20M11.75M43.83M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -14.69M-143.00K-260.00K-7.17M---12.23M-8.24M-4.77M-2.51M-5.38M--77.51M-82.03M-116.93M-32.25M
Investing Cash Flow -103.23M52.46M59.90M17.62M---2.17M2.10M--18.00K360.00K--2.71M-414.00K-103.00K-581.00K
Financing Cash Flow 555.00K-83.32M8.70M-34.24M---284.00K-14.10M5.81M75.45M-47.80M2.56M124.47M-239.00K
Capital Expenditure -----80.00K-195.00K-75.00K---18.00K---2.71M-414.00K-103.00K-581.00K
Free Cash Flow -------12.31M---2.53M---80.23M-82.44M-117.03M-32.83M
Net Change in Cash -------------32.42M-79.88M7.44M-33.07M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % -32.8%-81.5%-30.6%-35.8%76.3%------------
Net Margin % -16.9%-71.5%-22.8%-31.6%76.7%------------
ROE % -3.2%-36.5%-5.9%-26.2%65.3%-30.9%-48.2%-79.7%-122.8%-33.4%-21.0%-6.9%-12.8%-33.5%-70.7%-16.7%-122.3%
ROCE % --16.1%-4.1%-8.3%64.9%-31.0%-48.4%-80.3%-123.2%-33.9%-22.4%-7.0%-12.9%-35.1%-77.1%-97.0%-128.0%

Shareholding Pattern

Insiders
2.05%
Institutions
26.72%
Public Float
27.28%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard Capital Management LLC 4.09% 1.97M $1.43M
2 Two Sigma Investments, LP 3.54% 1.71M $1.24M
3 Marshall Wace LLP 3.31% 1.60M $1.16M
4 Blackrock Inc. 3.01% 1.45M $1.06M
5 Goldman Sachs Group Inc 1.38% 668.79K $485.54K
6 Geode Capital Management, LLC 1.27% 615.51K $446.86K
7 Shaw D.E. & Co., Inc. 1.00% 485.02K $352.13K
8 GMT Capital Corp 0.93% 450.10K $326.77K
9 Renaissance Technologies, LLC 0.81% 389.60K $282.85K
10 Squarepoint Ops LLC 0.66% 318.38K $231.14K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FLNA

Google News Fri, 13 Mar 2026

symbol__ Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE95Q0ZhaHNtMUprR1hod29kanBBYzF0c1lRZ2hndVFrNEdBclJoRDRrWHJyc3R0UnJtLTZ2MTZKNmJMdF9ORzBrN0N5Yy1CWGxV?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a>&nbsp;&nbsp;<fon…

Google News hu, 25 Jun 2026

FLNA Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBLcFBIekduaFJDZ0VPNFBxV2VaNS16MkJOajducW81WUpEV2RzelpkVmRLNUNYQ1VCaHJFcmQ3ZWJ0LVJTcjh1ZEw2YXFWZXZLZFlDdHVRTjdZeWVzMXlwd2VjZUt3WUt3WWVJYlg1V2doOURjRG1wQ1p3?oc=5" target="_blank">FLN…

Google News ue, 10 Mar 2026

Filamin A-focused Filana Therapeutics replaces Cassava Sciences - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNOFlXZUwyajNPYzlGNnFSV2pZVDFPcVh0MVJEWTdSdlVrbGJlTE14Vm1nNlFjM0dZcHpLaURydlFLa3FVUG9jbFlpQm5oSmFWRHg5SWw1dDlnTmFiRkdhRExGMWdWY1UxdW9pQVo5QW5wWFBqSE1uaFMzUnp0V2U2bF9UVVhTN2hvVjlIZW…

Google News Fri, 24 Apr 2026

Cassava Sciences (FLNA) Stock Price, News & Analysis $FLNA - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE1nNTF0dGN3M256WmZlaXp2SXVEaGI4ZE9iN2liZDZaeGpoVUh5endVOC1nWlVfTEY5Qk5CSEtZNS1VUUJ3NWJMYzZoVUhZdGt2ZFNhSWpPbFVxZw?oc=5" target="_blank">Cassava Sciences (FLNA) Stock Price, News & A…

Google News Wed, 27 May 2026

FLNA - Filana Therapeutics Inc Stock Price and Quote - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE91bEhZa05nR1g3cHkwT3BjMTdZMHRBZlpFMVRoWHpMdWVxbjYxX1ktZm1EaWRvV2VENGtJdWUtaTlzQlhfMFE?oc=5" target="_blank">FLNA - Filana Therapeutics Inc Stock Price and Quote</a>&nbsp;&nbsp;<fon…

Google News Fri, 13 Mar 2026

Filana Therapeutics - FLNA - Stock Price & News - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBiU0gwQXFRTHR0ckIxLWpmY3BIOXpiMHU0WDJiVkhWQ2F3OEw0VU05Y3VTYUJlRFRaQ3dGMEpzb1dEUmxkZ3NEY0xma1M3eXNB?oc=5" target="_blank">Filana Therapeutics - FLNA - Stock Price & News</a>&nbsp;&n…

FLNA — Frequently Asked Questions

What is the current share price of Filana Therapeutics, Inc. (FLNA)?

As of 2026-09-19 21:16 PDT, Filana Therapeutics, Inc. (FLNA) trades at $0.80 on NasdaqCM. Its 52-week range is $0.80 to $4.64.

What is the market capitalisation of FLNA?

Filana Therapeutics, Inc. (FLNA) has a market capitalisation of $38.65M on NasdaqCM.

What is the P/E ratio of FLNA?

FLNA trades at a trailing price-to-earnings (P/E) ratio of -0.92. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.61.

What is the return on equity (ROE) of FLNA?

FLNA has a return on equity (ROE) of -55.78%. Its return on capital employed (ROCE) is -128.00%.

Is FLNA a good stock to buy?

This page provides a data-driven analysis of Filana Therapeutics, Inc. (FLNA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space